|
Video: What is a Stock Split?
|
|
ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms. Co.'s focus is on renal and inflammatory diseases. The lead candidate in Co.'s renal pipeline is a Phase 2a-ready cholesterol efflux mediator, VAR 200, for focal segmental glomerulosclerosis (FSGS), an orphan renal disease. VAR 200 mediates removal of excess renal cholesterol and lipids that damage the kidneys and has potential to reduce proteinuria and delay disease progression. For treatment of inflammatory diseases, Co. is developing a monoclonal antibody that inhibits inflammasome ASC (IC 100). According to our ZVSA split history records, ZyVersa Therapeutics has had 2 splits. | |
|
ZyVersa Therapeutics (ZVSA) has 2 splits in our ZVSA split history database. The first split for ZVSA took place on December 05, 2023. This was a 1 for 35 reverse split, meaning for each 35 shares of ZVSA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 28.5714285714286 share position following the split. ZVSA's second split took place on April 26, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of ZVSA owned pre-split, the shareholder now owned 1 share. For example, a 28.5714285714286 share position pre-split, became a 2.85714285714286 share position following the split.
When a company such as ZyVersa Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ZVSA split history from start to finish, an original position size of 1000 shares would have turned into 2.85714285714286 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ZyVersa Therapeutics shares, starting with a $10,000 purchase of ZVSA, presented on a split-history-adjusted basis factoring in the complete ZVSA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/14/2022 |
|
End date: |
04/29/2024 |
|
Start price/share: |
$3,444.00 |
|
End price/share: |
$5.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.83% |
|
Average Annual Total Return: |
-94.51% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$16.73 |
|
Years: |
2.20 |
|
|
|
Date |
Ratio |
12/05/2023 | 1 for 35 | 04/26/2024 | 1 for 10 |
|
|